The Short Version
The claim is largely accurate. Large clinical trials and meta-analyses consistently show GLP-1 receptor agonists deliver meaningful cardiovascular, metabolic, and weight-loss benefits that outweigh the predominantly mild-to-moderate GI side effects most often featured in media. However, the net benefit is patient-specific, not universal. Emerging signals — including a 29% increased osteoporosis risk and an unresolved thyroid cancer concern — represent real long-term harms beyond media-hyped complaints. Benefit magnitudes are modest (10–20% reductions for most outcomes), and GI side effects cause meaningful treatment discontinuation.